The long-term antiproteinuric effect of eplerenone,a selective aldosterone blocker,in patients with non-diabetic chronic kidney disease

Abstract

Introduction: There is still insufficient data concerning the clinical effects of eplerenone, a selective aldosterone blocker, in patients with non-diabetic chronic kidney disease (CKD).

Methods: This study included non-diabetic CKD patients with urinary protein excretion (UPE) of 1.0 g/gCr or more in spite of long-term treatment with renin–angiotensin system (RAS) inhibitors. The clinical effects of eplerenone (25–50 mg/day) were investigated for 12 months.

Results: Eplerenone treatment was associated with a 38% reduction in UPE after 12 months. There was only a slight increase in the serum potassium level. The reduction of proteinuria was observed more prominently in patients with modestly impaired renal function than in those with preserved renal function at baseline.

Conclusion: The long-term administration of low-dose eplerenone was effective and safe for the treatment of non-diabetic CKD patients who showed persistent proteinuria in spite of therapy with RAS inhibitors.

Keywords

Chronic kidney disease eplerenone proteinuria renal function renin–angiotensin–aldosterone system

Get full access to this article

View all access options for this article.

References

Remuzzi

Benigi

Remuzzi

. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 2006; 116: 288–296.

Catapano

Chiodini

De Nicola

. Antiproteinuric response to dual blockade of the renin–angiotensin system in primary glomerulonephritis: meta-analysis and metaregression. Am J Kidney Dis 2008; 52: 475–485.

Parving

Person

Lewis

. AVOID Study investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358: 2433–2446.

Epstein

. Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Am J Med 2006; 119: 912–919.

Nagase

Yoshida

Shibata

. Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J Am Soc Nephrol 2006; 17: 3438–3446.

Bomback

Kshirsagar

Amamoo

. Change in proteinuria after adding aldosterone blocker to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis 2008; 51: 199–211.

Bianchi

Bigazzi

Campese

. Antagonist of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. Am J Kidney Dis 2005; 46: 45–51.

Sato

Hayashi

Saruta

. Antiproteinuric effects of mineralcorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens 2005; 18: 44–49.

Chrysostomou

Pedagogos

MacGregor

. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol 2006; 1: 256–262.

10.

Tylicki

Rutkowski

Renke

. Triple blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. Am J Kidney Dis 2008; 52: 486–493.

11.

Matsuo

Imai

Horio

.; Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982–992.

12.

Epstein

Williams

Weinberger

. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006; 1: 940–951.

13.

Ando

Ohtsu

Arakawa

. Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect Study Investigators. Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria. Hypertens Res 2010; 33: 616–621.